Q32 Bio prices $200 million stock offering, cites SIGNAL-AA Part B data

Q32 Bio Inc. priced a public offering dated July 14, 2026, consisting of 6,027,399 shares of common stock and pre-funded warrants to purchase up to 4,931,506 shares of common stock.¹ The per share purchase price of the common stock is $18.25.¹ The underwriters were Morgan Stanley, Jefferies, Cantor, and Oppenheimer & Co. as joint book-running managers, with H.C. Wainwright & Co. as lead manager.¹ The company also granted the underwriters a 30-day option to purchase up to an additional 1,643,835 shares at the public offering price, less underwriting discounts.¹

Q32 Bio estimated net proceeds of approximately $187.59 million, or approximately $215.79 million if the underwriters exercise their option in full.¹ The company intends to use proceeds together with existing cash for working capital, including research, clinical development and commercialization efforts supporting bempikibart's advancement into future clinical trials.¹

The filing also disclosed 36-week topline results from Part B of the SIGNAL-AA trial. In Part B, bempikibart was evaluated in 33 patients with severe or very severe alopecia areata, with baseline SALT scores of 50-100 and a maximum duration of current episode of four years.¹ At Week 36, the company reported a mean percent reduction in SALT score from baseline of 35.3% in the modified intent-to-treat analysis.¹ 40.0% of patients in the mITT analysis and 30.3% in the intent-to-treat analysis achieved a SALT-20 response.¹ Bempikibart was observed to have a generally well-tolerated safety profile in Part B, consistent with prior studies, with no new safety signals, and early signs of durability included one patient who achieved complete hair growth.¹

Q32 Bio said it intends to advance bempikibart into a registration-directed program in the first half of 2027 and plans to share full Part B results at a future medical meeting.¹ Separately, the company paid off the roughly $6.8 million remaining balance on its Silicon Valley Bank loan on June 24, 2026, terminating the agreement.¹